Skip to main content
    R

    Revolution Medicines Inc (RVMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $162.69
    -4.18 (-2.50%)

    Market Cap: $36.09B

    Last updated: Nov 17, 2026 at 4:43 PM ET

    Revolution Medicines Inc (RVMD) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Revolution Medicines (RVMD) has a market cap of $36.09B and an enterprise value of $35.96B. It kept -946.82% of revenue as net income over the last 12 months. Its share count is up 13.59% from a year earlier.

    Total Valuation

    Enterprise value is 0.35% below the market cap, as cash exceeds debt.

    Market Cap$36.09B
    Enterprise Value$35.96B
    Latest price (Nov 17, 2026)$162.69

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.92% in the quarter ended Sep 30, 2026 and grew 13.50% a year over 2 years.

    Shares Outstanding214.95M
    Shares Change (YoY)+13.59%
    Shares Change (QoQ)+1.92%
    Share Count Growth (2Y CAGR)+13.50%

    Valuation Ratios

    Sales and book value multiples are 177.0x and 14.6x. Its year-end P/S ranged from 28.0x to 249.4x from 2020 to 2024.

    P/S Ratio177.0x
    Forward P/S57.7x
    P/B Ratio14.6x
    P/TBV Ratio15.0x

    Valuation history and multiples

    Price Statistics

    The stock is up 140.13% over 52 weeks and trades 15.58% below its 50-day average.

    Beta (1Y)1.31
    52-Week Change+140.13%
    1-Month Change-10.68%
    3-Month Change-24.21%
    6-Month Change+10.45%
    5-Year Change+550.05%
    Total Return (1Y)+140.13%
    Total Return (3Y CAGR)+96.81%
    Total Return (5Y CAGR)+40.17%
    Return vs SPY (1Y)+118.95%
    Max Drawdown (1Y)-26.43%
    Max Drawdown (3Y)-48.63%
    Sharpe Ratio (1Y)1.32
    Correlation with SPY (1Y)0.28
    50-Day Average$192.71
    200-Day Average$160.55
    52-Week Range$69.50 to $224.31
    RSI (14 Days)35.4
    Average Volume (20 Days)2.39M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 8.36x current liabilities, and total debt is 0.20x shareholder equity.

    Current Ratio8.36x
    Quick Ratio8.34x
    Debt / Equity0.20x
    Interest Coverage-23.31x

    Returns and Efficiency

    Return on invested capital is -52.09% over the last 12 months, against a 5-year average of -35.45%.

    Return on Equity (ROE)-77.89%
    Return on Assets (ROA)-43.47%
    Return on Invested Capital (ROIC)-52.09%
    ROE (5Y Average)-37.42%
    ROA (5Y Average)-29.73%
    ROIC (5Y Average)-35.45%
    Asset Turnover0.06x
    Inventory Turnover0.06x
    Receivables Turnover1.71x
    Cash Conversion Cycle-99161 days

    Scores

    RVMD has an Altman Z-Score of 9.17, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score9.17
    Altman Z ZoneSafe
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $197.56M over the last 12 months is down 24.48% from the 12 months before.

    Revenue$197.56M
    Revenue Growth (YoY)-24.48%
    Gross Profit$192.53M
    Operating Income-$1.69B
    Pretax Income-$1.87B
    Net Income-$1.87B
    Reported EPS (TTM)-$8.39

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 55.81% of the $4.30B in total assets.

    Cash and Equivalents$615.91M
    Total Debt$487.88M
    Net Cash$128.03M
    Net Cash Per Share$0.60
    Working Capital$3.50B
    Shareholder Equity$2.40B
    Book Value Per Share$11.17
    Tangible Book Value$2.33B
    Tangible Book Per Share$10.85
    Total Assets$4.30B
    Total Liabilities$1.90B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $9.45M of capital spending, operating cash flow left -$1.44B of free cash flow.

    Operating Cash Flow-$1.43B
    Capital Expenditures$9.45M
    Free Cash Flow-$1.44B
    FCF Per Share-$6.72
    Depreciation and Amortization$17.81M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -852.98%.

    Gross Margin97.45%
    Operating Margin-852.98%
    Pretax Margin-948.02%
    Net Margin-946.82%
    FCF Margin-729.31%

    Growth

    Book Value Per Share Growth (2Y CAGR)-18.56%
    Tangible Book Per Share Growth (2Y CAGR)-18.71%

    Revenue and profit by year

    Dividends and Yields

    RVMD does not pay a dividend. Its free cash flow yield is -4.12%.

    FCF Yield-4.12%
    Buyback Yield-6.91%
    Shareholder Yield-6.91%

    Peer Position

    Against 11 similar companies, RVMD has the 2nd highest P/S.

    P/S Ratio177.0x vs 17.5x median
    ROIC-52.09% vs 4.83% median
    Revenue Growth (Trailing 4 Quarters, YoY)-24.48% vs +25.96% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RVMD

    What is RVMD's market cap?

    Revolution Medicines has a market cap of $36.09B. Its enterprise value, which adds debt and subtracts cash, is $35.96B.

    How many shares of RVMD are outstanding?

    Revolution Medicines has 214.95M shares outstanding. The count is up 13.59% from a year earlier.

    Does RVMD pay a dividend?

    No. Revolution Medicines does not pay a dividend.

    How much debt does RVMD have?

    Revolution Medicines has $487.88M of total debt and $615.91M of cash and equivalents, a net cash position of $128.03M.